Hepatitis Journal Options - Volume 3, Issue 2

Stay up to date with the current medical literature through a CME-certified learning module and CCO’s capsule summaries of the most relevant recently published articles with accompanying Expert Commentaries and downloadable slidesets.

Topics include:

• Telaprevir for chronic HCV genotype 1 infection
• Prolonged HCV therapy with low-dose peginterferon
• HCC in hepatitis C–related advanced liver disease
• Retreating chronic hepatitis C with daily interferon alfacon-1/ribavirin: DIRECT results
• Chronic hepatitis C genotype 4 treated with nitazoxanide, peginterferon, ribavirin
• Tenofovir vs adefovir for chronic hepatitis B
• Early serum HBsAg drop and SVR in HBeAg-negative patients
• Rifaximin for hepatic encephalopathy
• Effect of fatigue on driving skills in hepatic encephalopathy patients
  
  

HBV Treatment: What to Start?

CCO’s expert faculty members discuss the latest clinical data and best practices for selecting optimal initial HBV therapy, including a review of different initial management strategies for HBeAg-positive and HBeAg-negative patients with chronic HBV infection.

Now Available!

CME-Certified Module:

HBV Treatment: What to Start? Robert G. Gish, MD, describes the latest data and reviews the most recent guidelines on the optimal selection of first-line therapy for patients with chronic hepatitis B infection.

Downloadable CCO Slideset:

HBV Treatment: What to Start? Download slide highlights from the CME-certified module on initial HBV therapies for self study and use in your own noncommercial presentations.

CME-Certified Interactive Case Challenges:

Managing Initial Treatment for an Asian American Patient With HBeAg-Positive Chronic Hepatitis B Learn about frontline regimen selection and on-treatment management of an HBeAg-positive patient and apply this learning with Albert D. Min, MD, in this Interactive Case Challenge.

Management of Initial HBV Therapy for an HBeAg-Negative Patient Attempt this Interactive Case Challenge and learn strategies for frontline regimen selection and on-treatment management of patients with HBeAg-negative chronic HBV infection with Calvin Q. Pan, MD, FACP, FACG.

2009 Annual Meeting of the European Association for the Study of the Liver

CCO's coverage of the 2009 Annual Meeting of the European Association for the Study of the Liver includes Capsule Summaries of key presentations, as well as Expert Analyses, and audio Expert Highlights that focus on key issues highlighted at the conference.

• Advances in HBV Treatment: 2009 
  Maria Buti, MD; Anna S. F. Lok, MD; Patrick Marcellin, MD

• Update on the Management of HCV and the Complications of Liver Disease
  Adrian M. Di Bisceglie, MD, FACP; Michael P. Manns, MD; Stefan Zeuzem, MD

CME-Certified Expert Analyses:

Advances in HBV Treatment: 2009 Join Maria Buti, MD; Anna S. F. Lok, MD; and Patrick Marcellin, MD, as they review and discuss the latest data on the treatment of chronic HBV infection presented at the 2009 European Association for the Study of the Liver annual meeting.

Update on the Management of HCV and the Complications of Liver Disease Join Adrian M. Di Bisceglie, MD, FACP; Michael P. Manns, MD; and Stefan Zeuzem, MD, as they discuss the most clinically relevant new data presented at 2009 EASL regarding the treatment of HCV infection and the management of complications associated with advanced liver disease.

Hepatitis C Advanced Practice Curriculum 2009

Through 3 Interactive Virtual Presentations, CCO’s expert faculty members review recent data and discuss critical aspects of HCV disease management, including the importance of patient quality of life, topics pertaining to patient retreatment, and strategies for minimizing cirrhosis and liver disease progression.

Now Available!

CME-Certified Interactive Virtual Presentations:

2009 HCV Advanced Practice Curriculum: The Importance of Patient Quality of Life Vinod Rustgi, MD, discusses how hepatitis C infection impacts quality of life and how quality of life can impact the outcome of hepatitis C therapy. Downloadable PowerPoint Slideset available for review and use in your own noncommercial presentations.

2009 HCV Advanced Practice Curriculum: Current Management of HCV Treatment-Experienced Patients Maria H. Sjogren, MD, MPH, FACP, discusses current management options for HCV-infected, treatment-experienced patients. Downloadable PowerPoint Slideset available for review and use in your own noncommercial presentations.

New!

2009 HCV Advanced Practice Curriculum: Fibrosis and Disease Progression in HCV Raymond T. Chung, MD, reviews complications of advanced liver disease, how to assess the severity of liver disease, and how treatment may address these complications. Downloadable PowerPoint Slideset available for review and use in your own noncommercial presentations.

Multidisciplinary Strategies in the Management of Patients With Hepatocellular Carcinoma: A Video Roundtable

Expert faculty members review and explore regional and systemic treatment strategies for the clinical management of patients with hepatocellular carcinoma.

Now Available!

Video Panels:

Normal ALT in Patients With Chronic HBV: Implications for Patient Management

This new Treatment Update explores the role of ALT in monitoring and managing chronic hepatitis B. Discussions include the role of ALT as a marker of liver injury, the relationship between ALT levels and patient outcomes, and strategies for managing patients with normal ALT levels.

Now Available!

CME-Certified Interactive Virtual Presentation:

Clinical Utility of ALT in Diagnosis and Management of Chronic Hepatitis B W. Ray Kim, MD, discusses the importance of ALT in hepatitis B and outlines management approaches for patients with normal ALT levels.

Downloadable CCO Slideset:

Clinical Utility of ALT in Diagnosis and Management of Chronic Hepatitis B W. Ray Kim, MD, reviews the role of ALT in hepatitis B and outlines management strategies for patients with normal ALT levels.

Hepatitis Journal Options - Volume 3, Issue 1

Topics include:

• Individualized treatment duration for hepatitis C genotype 1 patients
• Rapid virologic response and treatment duration for chronic hepatitis C genotype 1 patients
• Peginterferon alfa-2a and ribavirin in hepatitis C patients with rapid virologic response
• Randomized study of higher doses of peginterferon alfa-2a and ribavirin
• Ribavirin exposure after first dose predictive of sustained virologic response
• Resistance to nitazoxanide or tizoxanide
• Sustained HBeAg and HBsAg loss
• Sorafenib in advanced hepatocellular carcinoma
  

Clinical Strategies for Preventing Drug Resistance in Chronic Hepatitis B

This new Treatment Update provides an overview of the mechanisms by which HBV develops resistance to antiviral therapy and outlines important treatment strategies for minimizing the risk of developing HBV resistance.

Now Available!

CME-Certified Modules:

	Mechanisms of Resistance to Anti-HBV Agents Maria Buti, MD, reviews the development of HBV antiviral resistance in the context of the life cycle of HBV and the mechanisms of action of antiviral drugs.
	Preventing Nucleos(t)ide Resistance in Treatment-Naive Patients Marc G. Ghany, MD, discusses oral agents for the treatment of chronic hepatitis B, their potency, and barriers to resistance and how this impacts the selection of initial treatment regimens.

Treatment of Thrombocytopenia in Patients With Chronic Hepatitis C: Potential Impact on Treatment Candidacy and Outcomes

In this new Treatment Update, CCO’s expert faculty members provide an overview of current approaches to the management and prevention of thrombocytopenia in the context of hepatitis C.

Now Available!

CME-Certified Module:

CME-Certified Interactive Virtual Presentation:

Downloadable Slideset:

Prevention and Management of Thrombocytopenia in Hepatitis C Patients In this downloadable slideset, Robert S. Brown, Jr., MD, MPH, reviews the impact of thrombocytopenia on the care of patients with chronic hepatitis C.

• HBV Providers’ Choice in Prime Time: Addressing Issues of Patient Populations, Resistance, Individualized Treatment, Management, and Efficacy
  CCO’s expert faculty members review recent data on pertinent issues in HBV treatment including management of HBV in the setting of pregnancy, the role of initial regimen selection in preventing resistance and virologic breakthrough, and the management of patients with partial response to therapy.
  
  
  
• Cases in Point: Risk Factors, Surveillance Strategies, and Treatment Options for Hepatocellular Carcinoma
  Review monitoring and surveillance recommendations for HCC, and emerging strategies for treatment and management.
  
  
  
• New Options for HCV Nonresponders: Navigating Emerging Data and Best Practices for Treatment-Experienced Patients 
  This Treatment Update is specifically designed for frontline providers, nurse practitioners, physician assistants, and others who treat patients who have been previously treated for HCV. It provides program participants with the latest data and best practices on management approaches for these patients as well as a means to synthesize these strategies through Interactive Case Challenges.
  
  
  
• Management of Depression and HCV: Novel Data, Best Practices, and Case Challenges
  Access certified-CME modules as well as Slidesets and interactive cases.
  
  
  
• HBV Core Curriculum 2008
  Join Robert G. Gish, MD, as he discusses the epidemiology and natural history of HBV. Then listen as Albert D. Min, MD, discusses the treatment and management of chronic hepatitis B virus infection.
  
  

• 2009 Annual Meeting of the European Association for the Study of the Liver
  
• 2008 Annual Meeting of the American Association for the Study of Liver Diseases
  

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

• Minimizing Barriers and Maximizing Response: Strategies and Tools for Frontline Providers Caring for Patients With Chronic Hepatitis C
  Interesting Interactive Case Challenges and Virtual Presentations that explore treatment decisions for patients with chronic hepatitis C.
  

• Management of Emergent Depression and Suicidal Ideation During HCV Therapy
  
  
  
• Management of a Patient Who Develops Psychiatric Adverse Events While Receiving Peginterferon Therapy for HCV
  
  
  
• Management of a 43 Year-Old HCV-Infected, Treatment-Naive Female With a History of Major Depression
  
  
  
• Retreatment of a Patient Failing Previous HCV Therapy 
  
  
  
• Management of an HCV-Infected Male With Advanced Liver Disease 
  
  
  
• Optimizing Treatment Success of a Second HCV Regimen in a Patient With Unsuccessful Initial Treatment With Peginterferon alfa-2a and Ribavirin 
  
  
  
  
  
   

Topics

• Fibrosis and Cirrhosis
• HBV
• HCV
• Hepatocellular Carcinoma
• HIV Coinfection
• Nash, ALD, etc.
• Other Hepatitis Viruses
• Transplantation

Resources

• Advanced Search
• Case Challenges
• Animations
• Live Events
• Slide Download Library
• Interactive Tools
• Bookstore

Rapid HCV RNA Decline in Treatment-Naive Genotype 1 Patients With ITMN-191 Combined With Peginterferon alfa-2a Plus Ribavirin

Patients receiving ITMN-191 combination therapy with peginterferon alfa-2a plus ribavirin experienced rapid HCV RNA decline with no virologic rebound.

Click here for related capsule summaries

Click here for the slide library.

Learn about frontline regimen selection and on-treatment management of an HBeAg-positive patient and apply this learning with Albert D. Min, MD, in this Interactive Case Challenge.

Click here for more cases.

Click here for more tools.